- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | Silo Pharma erhält kanadische Patentzulassung für PTSD-Wirkstoff SPC-15 | 2 | Investing.com Deutsch | ||
| 18.08. | Silo Pharma receives Canadian patent allowance for SPC-15 drug | 2 | Investing.com | ||
| 18.08. | Silo Pharma, Inc.: Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment | 425 | GlobeNewswire (Europe) | Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026... ► Artikel lesen | |
| 17.08. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Silo Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| 10.08. | Silo Pharma, Inc.: Silo Pharma Granted European Patent Covering Novel PTSD Therapy | 455 | GlobeNewswire (Europe) | Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms develop SARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 06.08. | Silo Pharma, Inc.: Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform | 3 | GlobeNewswire (USA) | ||
| 21.07. | Silo Pharma, Inc.: Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program | 2 | GlobeNewswire (USA) | ||
| 14.07. | Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership | 10 | Benzinga.com | ||
| 14.07. | Silo Pharma-Tochter QwikAgents tritt AMD KI-Entwicklerprogramm bei | 18 | Investing.com Deutsch | ||
| 14.07. | Silo Pharma, Inc.: Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform | 9 | GlobeNewswire (USA) | ||
| 10.07. | Silo Pharma Sinks on Stock Sale | - | Baystreet.ca | ||
| 10.07. | Aktien im Fokus: CCC Intelligent Solutions und Circle legen vorbörslich zu, Silo Pharma und Fermi America unter Druck | 3 | Investing.com Deutsch | ||
| 10.07. | Silo Pharma raises $4 million in private placement | 3 | Investing.com | ||
| 10.07. | Silo Pharma raises $4M in private placement; shares down | 4 | Seeking Alpha | ||
| 10.07. | Silo Pharma sichert sich 4 Millionen US-Dollar durch Privatplatzierung | 3 | Investing.com Deutsch | ||
| 10.07. | Silo Pharma, Inc.: Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 420 | GlobeNewswire (Europe) | $4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash SARASOTA, FLA., July 10, 2026 (GLOBE NEWSWIRE) -- Silo... ► Artikel lesen | |
| 07.07. | Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives | 5 | Benzinga.com | ||
| 07.07. | Silo Pharma subsidiary joins NVIDIA developer program | 3 | Investing.com | ||
| 07.07. | Silo Pharma, Inc.: Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program | 3 | GlobeNewswire (USA) |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,125 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target | ||
| EXELIXIS | 46,940 | -0,10 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff |
Das Unternehmen SILO PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILO PHARMA INC finden Sie auf Wallstreet Online.